Compare Corning Incorporated (GLW) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Heron Therapeutics Inc — how do they compare? Corning Incorporated trades at $158.89 (market cap $150.10B), while Heron Therapeutics Inc trades at $0.47 (market cap $84.50M). The key difference: Corning Incorporated is far larger — about 1776.3× Heron Therapeutics Inc's market cap, and Corning Incorporated pays a 0.64% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GLW | HRTX | |
|---|---|---|
Market Cap | $150.10B | $84.50M |
Sector | Technology | Health |
52-Week High | $255.79 | $2.02 |
52-Week Low | $52.97 | $0.39 |
Enterprise Value | $158.27B | $182.40M |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $187.68, up 2.36% today, with a neutral technical signal and bearish moving averages. Recent earnings beats and strong 2025 results, including $15.63B revenue and $1.60B net income, highlight fundamental strength. The stock has retreated from its June 2026 peak of $271.38, with analyst consensus pointing to a $210.10 price target. Key support lies at $185, with resistance at $191.
The outlook remains positive due to AI-driven optical communication demand and partnerships with NVIDIA and Amazon. Risks include market volatility and competitive pressures, but institutional sentiment is bullish with 54% buy ratings. Upside potential exists if the company maintains its earnings momentum and capitalizes on infrastructure spending trends.
HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.
The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
